Amneal Pharmaceuticals, Inc. reaffirmed earnings guidance for the year 2022. For the period, the company expects net revenue of $2.15 billion - $2.25 billion.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.79 USD | -0.29% | -0.15% | +11.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.53% | 2.1B | |
+43.85% | 749B | |
+39.18% | 605B | |
-6.61% | 351B | |
+19.61% | 328B | |
+7.97% | 292B | |
+11.69% | 216B | |
-2.54% | 214B | |
+1.70% | 167B | |
+6.94% | 165B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2022